The importance of FLC testing in MGUS patients
Monoclonal gammopathies of undetermined significance (MGUS) is a widespread phenomenon that increases markedly with age. While MGUS itself requires no medical action, the risk it poses for developing a blood cancer such as multiple myeloma (MM) is 1% per year. Detection and monitoring of MGUS are therefore critical to ensure early discovery of progression to MM. This is important because the earlier MM is treated, the better the chances of curing the disease.
This webinar highlights the key role of free light chain (FLC) testing in the detection and monitoring of MGUS and summarizes the results of recent studies.
Key learning objectives
- Understand when serum FLC (sFLC) should be utilized in MGUS diagnosis
- Find out how sFLC assessment is incorporated in risk stratification of MGUS
- Learn how to incorporate sFLC in monitoring of MGUS
Who should attend
- Endocrinologists
- Hematologists
- Hematologist-oncologists
- Hemopathologists
- Intensive care physicians
- Nephrologists
- Oncologists
Accreditation statement
SelectScience is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.